Yao Huiping, Shen Ting, Chen Yanwei, Zhou Yufeng, Liu Xiaoqing, Shen Xi
Department of Ophthalmology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Heliyon. 2024 Jul 6;10(14):e34241. doi: 10.1016/j.heliyon.2024.e34241. eCollection 2024 Jul 30.
This report describes a case of bilateral transient myopia with a shallow anterior chamber and ciliochoroidal detachment following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and indapamide intake.
A 37-year-old man with coronavirus disease 2019 (COVID-19) was referred to our department due to bilateral blurred vision. The patient had been treated with ibuprofen for fever and indapamide for uncontrolled blood pressure. After four days of indapamide intake, the patient complained of bilateral visual blurring. On ocular examination, his uncorrected visual acuity was 20/400 in both eyes. Slit-lamp examination revealed shallow anterior chambers. The following day, the patient experienced pain and redness in both eyes, which began the previous night. Ocular examination revealed a significant decrease in intraocular pressure (IOP) compared to the previous day: 11 mmHg and 12 mmHg in the right eye (OD) and left eye (OS), respectively. Slit-lamp examination revealed conjunctival injection and the presence of inflammatory cells (2+) in the shallow anterior chambers of both eyes. Ultrasound biomicroscopy revealed ciliary body detachment and B-scan ultrasonography showed peripheral shallow choroidal detachment in both eyes. Discontinuing indapamide and initiating treatment with oral prednisolone, topical tobramycin dexamethasone and tropicamide phenylephrine eye drops resulted in the rapid recovery of signs and symptoms after three days.
Indapamide intake may contribute to bilateral ciliochoroidal detachment, with SARS-CoV-2 infection possibly increasing susceptibility to drug-induced side effects. Timely drug withdrawal and symptomatic treatment can result in a good prognosis.
本报告描述了1例新型冠状病毒2（SARS-CoV-2）感染并服用吲达帕胺后出现双眼短暂性近视、前房变浅及睫状体脉络膜脱离的病例。
一名37岁的新型冠状病毒肺炎（COVID-19）患者因双眼视力模糊转诊至我科。该患者曾服用布洛芬退热，服用吲达帕胺控制血压。服用吲达帕胺4天后，患者主诉双眼视力模糊。眼科检查显示，其双眼裸眼视力均为20/400。裂隙灯检查发现前房变浅。次日，患者双眼出现疼痛和眼红，症状始于前一晚。眼科检查显示，与前一天相比眼压显著降低：右眼（OD）为11 mmHg，左眼（OS）为12 mmHg。裂隙灯检查发现结膜充血，双眼前房变浅处有炎性细胞（2+）。超声生物显微镜检查发现睫状体脱离，B超检查显示双眼周边脉络膜脱离。停用吲达帕胺，并开始口服泼尼松龙、局部使用妥布霉素地塞米松和托吡卡胺去氧肾上腺素滴眼液治疗，3天后症状和体征迅速缓解。
服用吲达帕胺可能导致双眼睫状体脉络膜脱离，SARS-CoV-2感染可能增加药物不良反应的易感性。及时停药和对症治疗可取得良好预后。
